Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · AETHLON MEDICAL INC (AEMD)

Aethlon Medical amends CEO and CMO employment agreements on change-in-control severance

Neutral Impact 2 of 5 leadership Written later

Aethlon Medical amended the employment agreements of CEO and CFO James B. Frakes and Chief Medical Officer Steven P. LaRosa, M.D., on September 11, 2026. Under the amendments, if a change in control is completed and the executive is terminated in a way that triggers severance, installment severance and COBRA health care payments would be paid as a single lump sum. The filing states the amendments do not change the amount of severance or the circumstances that trigger it.

Key points

  • Amendments dated September 11, 2026, covering James B. Frakes (CEO and CFO) and Steven P. LaRosa, M.D. (Chief Medical Officer)
  • Severance installments become a single lump sum payable on the first regular payroll date after the release effective date, if a change in control and qualifying termination occur together
  • Health care continuation payments become a fixed lump sum equal to the COBRA period amount and are not reduced if the executive obtains other group coverage
  • The filing states the severance amounts and eligibility terms are unchanged

The filing

CompanyAETHLON MEDICAL INC (AEMD)
Form8-K, current report
Filed with the SECSep 15, 2026, 8:17 AM ET
Accession number0001683168-26-007126

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 15, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.